Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

AIMS: To evaluate potential differences between PF‐05280586 and rituximab sourced from the European Union (rituximab‐EU) and USA (rituximab‐US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Williams, Jason H., Hutmacher, Matthew M., Zierhut, Matthew L., Becker, Jean‐Claude, Gumbiner, Barry, Spencer‐Green, George, Melia, Lisa A., Liao, Kai‐Hsin, Suster, Matthew, Yin, Donghua, Li, Ruifeng, Meng, Xu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Pharmacokinetic Dynamic Relationships
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099556/
https://ncbi.nlm.nih.gov/pubmed/27530379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados